Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Authors
Keywords
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Overall Response Rate, Chronic Lymphocytic Leukemia Patient, Chronic Lymphocytic Leukemia Cell
Journal
Journal of Hematology & Oncology
Volume 9, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-03-09
DOI
10.1186/s13045-016-0250-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia
- (2015) J. R. Brown et al. BLOOD
- A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
- (2015) H. S. Walter et al. BLOOD
- The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity inCXCR4Wild-typeandCXCR4WHIMmutated Waldenstrom macroglobulinaemia cells
- (2015) Yang Cao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor
- (2015) Na Li et al. CANCER RESEARCH
- Abstract 2596: ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients
- (2015) Todd Covey et al. CANCER RESEARCH
- Abstract 408: ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer
- (2015) Brian J. Lannutti et al. CANCER RESEARCH
- Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma
- (2015) Q. Yang et al. CLINICAL CANCER RESEARCH
- Novel ALK inhibitors in clinical use and development
- (2015) Chaitanya Iragavarapu et al. Journal of Hematology & Oncology
- Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia
- (2015) Kanti R. Rai Journal of Hematology & Oncology
- Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway
- (2015) Kaimin Hu et al. Journal of Hematology & Oncology
- AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
- (2015) Jingjing Wu et al. Journal of Hematology & Oncology
- Blinatumomab: a new era of treatment for adult ALL?
- (2015) Xavier Thomas LANCET ONCOLOGY
- A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19+tumor cells
- (2015) Uwe Reusch et al. mAbs
- MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract 1744: ACP-196: A second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma
- (2015) Heather L. Gardner* et al. CANCER RESEARCH
- Abstract 1757: The novel BTK inhibitor CC-292 exerts in vitro and in vivo antitumor activity, interferes with adhesion, cell migration, and synergizes with lenalidomide in MCL models
- (2015) Anna Vidal-Crespo et al. CANCER RESEARCH
- Abstract 2624: The novel Bruton's tyrosine kinase inhibitor ACP-196 showsin vivoefficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model
- (2015) Carsten U. Niemann et al. CANCER RESEARCH
- New antibody approaches to lymphoma therapy
- (2014) Tejas Suresh et al. Journal of Hematology & Oncology
- Selective inhibitors of nuclear export (SINE)– a novel class of anti-cancer agents
- (2014) Kaushal Parikh et al. Journal of Hematology & Oncology
- Movement toward Optimization of CLL Therapy
- (2014) Kanti R. Rai et al. NEW ENGLAND JOURNAL OF MEDICINE
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy
- (2013) S E M Herman et al. LEUKEMIA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
- (2013) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More